Click Therapeutics faces reimbursement test as Motivista opens new schizophrenia treatment market

Click Therapeutics has secured FDA clearance for Motivista, giving the privately held digital-health company control of the first authorized U.S. treatment specifically indicated for the negative symptoms of schizophrenia and setting up a broader test of whether prescription software can scale in serious mental illness. The smartphone-based therapy is designed to complement antipsychotic medication rather than replace it, targeting persistent problems such as low motivation, reduced pleasure and social withdrawal that often remain after hallucinations and delusions are stabilized. With regulatory risk now substantially reduced, the commercial challenge shifts toward psychiatrist adoption, payer reimbursement and whether patients continue using the program outside a controlled clinical trial. Click Therapeutics is already preparing Motivista for wider availability and says it is working with health insurers, providers and patient organizations to establish access.

The company enters that commercialization phase with substantially more control over the asset than it originally expected. Boehringer Ingelheim transferred full product responsibility and commercial rights for Motivista, previously known as CT-155, to Click Therapeutics while simultaneously investing $50 million through a Series D financing and providing additional dedicated commercial funding. That arrangement leaves Click Therapeutics with greater potential upside if Motivista gains broad coverage, but it also places the burden of building a sustainable market largely on a company trying to prove that regulated digital therapeutics can succeed commercially after years of reimbursement uncertainty across the sector.

Motivista gives Click Therapeutics access to a treatment gap conventional schizophrenia drugs have not filled

Schizophrenia treatment has traditionally centered on antipsychotic medicines that reduce positive symptoms such as hallucinations, delusions and disorganized thinking. Those therapies can be highly important for stabilizing disease, but persistent negative symptoms frequently continue to impair social interaction, motivation, enjoyment and everyday functioning.

Motivista enters that gap with a distinctly different therapeutic model. Rather than acting on a neurotransmitter receptor, the software delivers structured behavioral and cognitive interventions through a smartphone and is intended for adults whose positive symptoms are already clinically stable while receiving clinician-managed outpatient care, including antipsychotic medication.

Click Therapeutics estimates that negative symptoms affect a substantial proportion of people with schizophrenia and contribute heavily to long-term disability. The condition itself affects roughly 24 million people globally and carries one of the highest societal costs per patient among mental-health disorders, creating an economically significant problem even before accounting for the difficulty of treating negative symptoms specifically.

That does not mean every person with schizophrenia becomes a commercial candidate for Motivista. The authorized population is deliberately narrower, excluding patients with unstable positive symptoms and requiring continued clinician involvement. Commercial uptake will therefore depend on how easily psychiatrists can identify appropriate patients and incorporate a digital prescription into existing treatment workflows.

The absence of another FDA-authorized therapy specifically for negative symptoms nevertheless gives Motivista a differentiated starting position. Click Therapeutics does not have to persuade physicians that its software is merely another version of an existing treatment; instead, it can position the product around an unmet symptom domain for which conventional pharmacotherapy has historically produced limited benefit.

Phase III efficacy gives Motivista a clinical argument, but commercial value will depend on real-world engagement

The pivotal CONVOKE study gives Click Therapeutics a stronger commercialization foundation than many earlier digital-health products received. The randomized Phase III trial enrolled 457 adults with schizophrenia who were already taking stable antipsychotic therapy and compared CT-155 with a digital control over 16 weeks.

Motivista produced a 6.8-point improvement on the Motivation and Pleasure subscale of the Clinical Assessment Interview for Negative Symptoms compared with a 4.2-point improvement in the control group. The effect size was approximately 0.36 and the difference was statistically significant, providing the evidence needed to support the FDA clearance.

Those numbers give Click Therapeutics a measurable efficacy story for psychiatrists and payers, but they do not eliminate one of the central commercial risks associated with digital therapeutics: adherence.

A pharmaceutical product can retain biological activity after each swallowed tablet or injection, while a behavioral digital therapeutic depends on patients repeatedly opening and engaging with software. That creates a particular challenge in schizophrenia because reduced motivation is itself one of the symptoms Motivista is intended to treat.

Trial engagement was therefore an important part of the development program. More than 70% of participants assigned to CT-155 remained active through the later stages of treatment, suggesting that patients with schizophrenia can engage consistently with the intervention under clinical-study conditions. Click Therapeutics will now need to determine whether comparable usage persists once the product enters routine care, where patients receive less structured research-site contact.

Real-world data could eventually become as commercially important as the original Phase III result. Insurers deciding whether to cover Motivista at scale are likely to want evidence that patients continue using the product and that symptom improvement translates into broader gains such as better daily functioning, reduced healthcare utilization or fewer costly episodes of deterioration.

Medicaid and payer coverage could determine whether Motivista becomes a scalable schizophrenia franchise

FDA clearance gives Click Therapeutics permission to market Motivista, but it does not guarantee reimbursement. That distinction has historically been one of the largest barriers facing prescription digital therapeutics.

Digital therapeutics occupy an unusual position within the healthcare system. They can undergo clinical trials and regulatory review like medical products, yet reimbursement pathways may be less standardized than those used for conventional pharmaceuticals. Physicians also need practical systems for prescribing, onboarding and monitoring patients, while insurers need a clear framework for deciding what they are willing to pay.

Click Therapeutics has already signaled that payer engagement is a central part of its strategy. The company specifically highlighted commercial discussions involving insurers and state Medicaid programs while preparing Motivista for broader availability.

Medicaid could be especially important because schizophrenia disproportionately contributes to long-term disability and public healthcare spending. A therapy that improves motivation and daily engagement could potentially create value beyond symptom scores if it helps patients participate more consistently in work, education, relationships or treatment.

Those broader economic benefits have not yet been established through the Phase III program. CONVOKE demonstrated improvement in negative symptoms, not reductions in hospitalization, disability claims or total healthcare costs.

That means Click Therapeutics will likely need to build a health-economic case alongside its clinical one. If Motivista can demonstrate that the cost of providing the software is offset by improved functioning or lower healthcare utilization, payer negotiations could become substantially easier. Without that evidence, insurers may view the product as an additional expense layered on top of antipsychotic therapy rather than a substitute for existing costs.

Boehringer Ingelheim’s $50 million investment gives Click Therapeutics capital and full commercial control

Motivista originally emerged from a collaboration between Click Therapeutics and Boehringer Ingelheim that began in 2020. Under the earlier agreement, Click Therapeutics was primarily responsible for research and development while Boehringer Ingelheim was expected to lead worldwide commercialization, with the original partnership carrying potential payments exceeding $500 million plus royalties.

That commercial structure changed substantially in 2026. Boehringer Ingelheim transferred full responsibility for CT-155, including marketing and commercialization rights, to Click Therapeutics and simultaneously invested $50 million through a Series D financing. Additional dedicated funding was also provided specifically to support commercialization.

The revised arrangement gives Click Therapeutics more strategic freedom and potentially greater economics from future sales. Instead of collecting royalties from a partner-controlled launch, the company can directly shape pricing, market access, distribution and physician engagement.

The trade-off is execution risk. Commercializing a schizophrenia product nationally requires relationships with psychiatrists, health systems, insurers and public payers that differ from the capabilities needed to develop software and run clinical trials.

Boehringer Ingelheim’s decision to fund the transition can be interpreted as continued financial support for the product rather than abandonment of the underlying technology. The pharmaceutical company remains associated with CT-155 while Click Therapeutics assumes the primary responsibility for turning the regulatory milestone into a commercial business.

For Click Therapeutics, that makes Motivista more than another pipeline product. It is now an important demonstration of whether the company can own both development and commercialization of a prescription digital therapeutic rather than relying primarily on larger pharmaceutical partners.

Motivista adds another FDA-authorized product to Click Therapeutics’ expanding digital pipeline

The schizophrenia clearance also strengthens Click Therapeutics’ broader platform story. The company has been building a portfolio of software-based treatments across psychiatry and neurology rather than relying on a single digital therapeutic.

Its pipeline includes CT-132, an FDA-authorized digital therapeutic for episodic migraine, as well as programs spanning depression, obesity, cardiometabolic disease and additional neurological and psychiatric indications. Click Therapeutics also collaborates with companies including Boehringer Ingelheim and Otsuka Pharmaceutical on selected programs.

That portfolio can potentially create operating leverage if the company develops common infrastructure for patient onboarding, clinician integration, reimbursement and software maintenance. A commercial system built for Motivista could later support additional digital products without requiring the same investment from scratch.

The reverse is also true. If reimbursement remains difficult even after strong clinical evidence and FDA clearance, that would raise questions about the economics of the broader prescription digital therapeutic model.

Motivista may therefore become an unusually important commercial test case for the industry. Its target population has a substantial unmet need, the pivotal study was randomized and controlled, and the product is the first authorized therapy specifically aimed at its symptom domain. Those attributes remove several of the scientific objections that have complicated adoption of less rigorously tested wellness applications. The remaining obstacles are primarily commercial and operational: who pays for the therapy, how physicians prescribe it, how patients are supported and whether engagement remains high enough to produce durable benefit.

Click Therapeutics now has to prove FDA authorization can translate into a sustainable digital-treatment business

Click Therapeutics is privately held, so there is no publicly traded stock reaction that can be used to assess immediate investor sentiment around the FDA decision. The more meaningful financial signals are therefore its recent financing and strategic ownership changes.

Boehringer Ingelheim’s $50 million investment gives the company additional capital as it prepares for commercialization, while the dedicated launch funding reduces some of the near-term burden associated with building market access and distribution capabilities.

The opportunity is significant precisely because the clinical problem is difficult. Negative symptoms can remain persistent for years and contribute substantially to unemployment, social isolation and reduced independence even after positive symptoms are controlled. A product that produces measurable improvement without adding conventional pharmacologic toxicity could occupy a useful place alongside antipsychotic treatment.

The FDA clearance does not guarantee that place. Physicians still need to prescribe Motivista, patients need to use it, and insurers need to agree that the incremental benefit justifies reimbursement.

Those questions will now determine whether Motivista becomes primarily a regulatory milestone or a meaningful new commercial franchise. If Click Therapeutics can demonstrate strong real-world engagement and persuade Medicaid programs and private insurers to cover the treatment, the company could establish a scalable model for prescription software in serious mental illness.

If reimbursement or usage remains limited, the clearance may instead highlight the continuing gap between regulatory validation and commercial adoption in digital therapeutics. Motivista has solved the first problem; Click Therapeutics now has to solve the second.

Key takeaways from Motivista’s FDA clearance and Click Therapeutics’ commercialization strategy

• Motivista is the first FDA-authorized treatment specifically indicated for negative symptoms of schizophrenia in clinically stable adults.
• The prescription digital therapeutic is used alongside clinician-managed care and antipsychotic medication rather than replacing standard pharmacologic treatment.
• Phase III CONVOKE data showed a statistically significant improvement in motivation and pleasure symptoms versus a digital control.
• Commercial success will depend heavily on sustained patient engagement because therapeutic benefit requires repeated interaction with the software.
• Click Therapeutics is already working with insurers, healthcare providers and state Medicaid programs as it prepares Motivista for broader availability.
• Boehringer Ingelheim transferred full commercial rights to Click Therapeutics and invested $50 million through a Series D financing.
• Full product ownership gives Click Therapeutics greater potential economics from Motivista but also places more launch and reimbursement responsibility on the company.
• Real-world evidence on functioning, healthcare utilization and long-term engagement could become important for convincing payers of Motivista’s economic value.
• The launch will provide a significant test of whether FDA-authorized digital therapeutics can build sustainable commercial franchises in serious mental illness.